Open AccessDifference in thrombotic microangiopathy between concurrently and previously diagnosed systemic lupus erythematosus
Author(s) -
Wen Chun Chen,
PoShen Ko,
HaoYuan Wang,
Yao Chung Liu,
Liang Tsai Hsiao,
Jyh Pyng Gau,
Jin Hwang Liu
Publication year - 2020
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000344
Subject(s) - medicine , thrombotic microangiopathy , microangiopathic hemolytic anemia , systemic lupus erythematosus , anemia , thrombotic thrombocytopenic purpura , microangiopathy , gastroenterology , disease , dermatology , diabetes mellitus , platelet , endocrinology
Thrombotic microangiopathy (TMA) syndromes are potentially life-threatening complications and are defined as integrated syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect various organs, including the hematopoietic system. SLE can complicate with TMA and can be categorized into two distinct groups by chronological association: TMA occurring as the initial presentation and leading to a diagnosis of SLE concurrently (TMA-cSLE) or TMA developing in patients previously diagnosed as having SLE (TMA-pSLE). We examined the differences in clinical characteristics, treatment responses, and clinical outcomes between these groups.